Heritage Investors Management Corp decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,242 shares of the healthcare product maker’s stock after selling 710 shares during the quarter. Heritage Investors Management Corp’s holdings in Abbott Laboratories were worth $2,783,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Lawson Kroeker Investment Management Inc. NE purchased a new position in Abbott Laboratories during the second quarter worth approximately $218,000. Dynamic Advisors Solutions LLC lifted its position in Abbott Laboratories by 0.4% during the second quarter. Dynamic Advisors Solutions LLC now owns 25,664 shares of the healthcare product maker’s stock worth $1,248,000 after buying an additional 103 shares in the last quarter. Koshinski Asset Management Inc. lifted its position in Abbott Laboratories by 8.9% during the second quarter. Koshinski Asset Management Inc. now owns 8,124 shares of the healthcare product maker’s stock worth $395,000 after buying an additional 667 shares in the last quarter. City Holding Co. lifted its position in Abbott Laboratories by 1.4% during the second quarter. City Holding Co. now owns 51,683 shares of the healthcare product maker’s stock worth $2,512,000 after buying an additional 726 shares in the last quarter. Finally, Country Club Trust Company n.a. lifted its position in Abbott Laboratories by 0.5% during the second quarter. Country Club Trust Company n.a. now owns 7,320 shares of the healthcare product maker’s stock worth $356,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 71.50% of the company’s stock.

Shares of Abbott Laboratories (ABT) traded up 1.215% during midday trading on Friday, hitting $52.055. The stock had a trading volume of 2,888,557 shares. The stock has a 50-day moving average price of $50.15 and a 200-day moving average price of $47.04. The stock has a market cap of $90.44 billion, a P/E ratio of 72.906 and a beta of 1.06. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $52.60.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. The business had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The business’s quarterly revenue was up 24.5% on a year-over-year basis. During the same period last year, the company posted $0.55 EPS. Equities analysts forecast that Abbott Laboratories will post $2.49 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Investors of record on Friday, October 13th will be given a $0.265 dividend. This represents a $1.06 annualized dividend and a dividend yield of 2.04%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 149.30%.

In other Abbott Laboratories news, insider Sharon J. Bracken sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total value of $98,320.00. Following the transaction, the insider now directly owns 28,806 shares of the company’s stock, valued at $1,416,102.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Hubert L. Allen sold 4,600 shares of the firm’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $50.79, for a total value of $233,634.00. Following the completion of the transaction, the insider now directly owns 105,479 shares in the company, valued at $5,357,278.41. The disclosure for this sale can be found here. Insiders sold a total of 218,150 shares of company stock worth $10,811,179 over the last ninety days. Corporate insiders own 0.76% of the company’s stock.

A number of equities research analysts have commented on ABT shares. TheStreet upgraded Abbott Laboratories from a “c+” rating to a “b” rating in a research report on Monday, July 3rd. Jefferies Group LLC restated a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a research report on Thursday, June 29th. Guggenheim started coverage on Abbott Laboratories in a research report on Thursday, June 29th. They issued a “buy” rating and a $58.00 target price on the stock. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, June 21st. Finally, BTIG Research started coverage on Abbott Laboratories in a research report on Wednesday, June 21st. They issued a “buy” rating and a $56.00 target price on the stock. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $52.71.

TRADEMARK VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/22/heritage-investors-management-corp-has-2-78-million-position-in-abbott-laboratories-abt.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.